Skip navigation


Current DateTime: 11:18:56 14 Nov 2009
LinksList Documentid: 24355697

FEATURED QUIZZES


Current DateTime: 11:18:56 14 Nov 2009
LinksList Documentid: 33793611
  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?

  • The Many Myths of Coca-Cola

      Can you tell which statements are true, and which ones are just rumors?

  • Think You Understand Markets?

      We've selected some questions from the Financial Industry Regulatory Authority's test of investor knowledge. See how you do ...


Current DateTime: 11:18:56 14 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Amgen Shares Leap on Osteoporosis Trial Results
By: Reuters | 28 Jul 2008 | 10:49 AM ET
Text Size

Shares of Amgen surged Monday after the company reported positive trial results for its osteoporosis drug candidate denosumab—which one analyst terms "a future blockbuster."

After the market closed Friday, Amgen reported late-stage clinical trial results that showed denosumab reduced the incidence of fractured vertebrae in post-menopausal women. Serious side effects were similar to a placebo injection—which, analysts said, will help eliminate concerns about the drug's safety.

The most common side effects were back and joint pain, hypertension and inflamed nasal passages.

Amgen [AMGN  Loading...      ()   ] stock climbed more than $7, or 13 percent, to almost $61 after the opening bell.

Rodman & Renshaw analyst Michael King said the results provide clearer data about the benefits and risks of denosumab. Because the side effects were similar to a placebo, he said, the drug's status as "a future blockbuster" is secure.

King raised his rating on Amgen stock to "market outperform" from "market perform," with a price target of $80 per share.

Jefferies analyst Adam Walsh also upgraded the Thousand Oaks, Calif., company to "buy" from "hold" and raised his target to $71 from $47. He estimated peak sales of $2 billion to $3 billion for denosumab—while May-Kin Ho of Goldman Sachs said sales could reach $5 billion if the drug is also approved to treat hormone-induced bone loss in cancer.

Ho said Amgen should report data from a cancer trial in late 2008 or early 2009, and she expects the drug to reach the market in 2010.

She raised her price target to $74 per share from $63.

Amgen is scheduled to release second-quarter results after the bell. Analysts on average expect earnings of $1.02 cents a share, on revenue of $3.58 billion, according to analyst estimates.

Copyright 2009 Reuters. Click for restrictions.
Tools:
Print EmailAdd This share icon
  • digg share

CNBC HIGHLIGHTS

  • Warren Buffett and Bill Gates spoke to Columbia students, and Buffett made the students a startling offer.
  • Brian L. Roberts
  • For the chief of cable company Comcast, growth has been about making deals – generally very large deals.
  • Some companies may start using insurance to shift carbon risk from their balance sheets to maybe... yours?
  • The president and founder of Genesis Today wants to improve America’s health, and thinks Wal-Mart can help.
  • Switzerland's privacy watchdog is taking legal action to force Google to make changes to its Street View service.
  • A wealthy, distracted Texas driver crashed his million-dollar Bugatti Veyron sports car into a salt marsh, say police.
ADD COMMENTS
Remaining characters


Current DateTime: 01:02:29 14 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:05:03 14 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:05:03 14 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:05:03 14 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters